Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15111344rdf:typepubmed:Citationlld:pubmed
pubmed-article:15111344lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0007097lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0014871lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C1704242lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0023413lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C1511237lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C1705509lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C1550436lld:lifeskim
pubmed-article:15111344lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:15111344pubmed:issue5lld:pubmed
pubmed-article:15111344pubmed:dateCreated2004-4-27lld:pubmed
pubmed-article:15111344pubmed:abstractTextCombination chemotherapy with continuous 5-fluorouracil (5-FU) and cisplatin in a monthly regimen is one of the standard treatments for advanced gastric carcinoma. This study evaluated the new LV5FU2-P regimen, designed to improve efficacy and tolerance of the 5-FU plus cisplatin combination.lld:pubmed
pubmed-article:15111344pubmed:languageenglld:pubmed
pubmed-article:15111344pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111344pubmed:citationSubsetIMlld:pubmed
pubmed-article:15111344pubmed:statusMEDLINElld:pubmed
pubmed-article:15111344pubmed:monthMaylld:pubmed
pubmed-article:15111344pubmed:issn0923-7534lld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:RougierPPlld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:DucreuxMMlld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:TaïebJJlld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:MitryEElld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:ArtruPPlld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:BoigeVVlld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:VaillantJ-NJNlld:pubmed
pubmed-article:15111344pubmed:authorpubmed-author:Clavero-Fabri...lld:pubmed
pubmed-article:15111344pubmed:issnTypePrintlld:pubmed
pubmed-article:15111344pubmed:volume15lld:pubmed
pubmed-article:15111344pubmed:ownerNLMlld:pubmed
pubmed-article:15111344pubmed:authorsCompleteYlld:pubmed
pubmed-article:15111344pubmed:pagination765-9lld:pubmed
pubmed-article:15111344pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:meshHeadingpubmed-meshheading:15111344...lld:pubmed
pubmed-article:15111344pubmed:year2004lld:pubmed
pubmed-article:15111344pubmed:articleTitleCombination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma.lld:pubmed
pubmed-article:15111344pubmed:affiliationHepato-Gastroenterology and Digestive Oncology, CHU Ambroise Paré, 9 Avenue Charles de Gaulle, AP-HP, F-92100 Boulogne-Billancourt, France. emmanuel.mitry@apr.ap-hop-paris.frlld:pubmed
pubmed-article:15111344pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15111344pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15111344lld:pubmed